|
See related Zyvox information |
|
|
|
Manufacturer |
Pfizer |
|
Distributor |
Hong Kong: Zuellig/Macau: The Glory Medicina |
|
Contents |
Linezolid |
|
Indications |
Listed in Dosage.
Click to view Zyvox detailed prescribing infomation |
|
Dosage |
Complicated skin & skin structure infections, community-acquired pneumonia including concurrent bacteremia, nosocomial pneumonia Adult & adolescent ≥12 yr 600 mg IV or PO 12 hrly. Childn from birth-11 yr 10 mg/kg IV or PO 8 hrly. All doses to be given for 10-14 days. Vancomycin-resistant Enterococcus faecium infections including concurrent bacteremia Adult & adolescent ≥12 yr 600 mg IV or PO 12 hrly. Childn from birth-11 yr 10 mg/kg IV or PO 8 hrly. All doses to be given for 14-28 days. Uncomplicated skin & skin structure infections Adult 400 mg PO 12 hrly. Adolescent 600 mg PO 12 hrly. Childn 5-11 yr 10 mg/kg PO 12 hrly; <5 yr 10 mg/kg PO 8 hrly. All doses to be given for 10-14 days.
Click to view Zyvox detailed prescribing infomation |
|
Overdosage |
View Zyvox overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Hypersensitivity. Concomitant MAOIs (eg phenelzine, isocarboxacid), directly & indirectly acting sympathomimetics (eg pseudoephedrine), vasopressive agents (eg epinephrine, norepinephrine), dopaminergic agents (eg dopamine, dobutamine), serotonin re-uptake inhibitors, TCAs, serotonin 5-HT1 receptor agonists (triptans), meperidine & buspirone. Patients w/ uncontrolled HTN, pheochromocytoma, thyrotoxicosis; carcinoid syndrome; catheter-related blood stream or catheter site infections.
Click to view Zyvox detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Zyvox detailed prescribing infomation |
|
Special Precautions |
Monitor CBC wkly in patients who receive linezolid for >2 wk w/ preexisting myelosuppression, receive concomitant drugs that produce bone marrow suppression or w/ chronic infection who receive previous or concomitant antibiotics. Discontinue if myelosuppression develops or worsens. Clostridium difficile-associated diarrhea must be considered in patient w/ diarrhea following antibiotic use. Lactic acidosis. Monitor for signs & symptoms of serotonin syndrome eg cognitive dysfunction, hyperpyrexia, hyperreflexia & incoordination. Peripheral & optic neuropathy. Monitor visual function. Convulsion. Overgrowth of nonsusceptible microorganisms. Uncontrolled HTN, pheochromocytoma, carcinoid syndrome, untreated hyperthyroidism. Phenylketonurics. May impair ability to drive or operate machinery. Pregnancy & lactation.
Click to view Zyvox detailed prescribing infomation |
|
Adverse Drug Reactions |
Diarrhea, headache, nausea. Oral & vag moniliasis, HTN, dyspepsia, localized abdominal pain, pruritus & tongue discolouration.
View ADR Monitoring Form |
|
Drug Interactions |
Adrenergic & serotonergic agents, food or beverage w/ high tyramine content. Strong CYP450 inducers eg rifampin, carbamazepine, phenytoin, phenobarb.
View more drug interactions with Zyvox |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Zyvox detailed prescribing infomation |
|
Storage |
View Zyvox storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Zyvox description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Zyvox mechanism of action for pharmacodynamics and pharmacokinetics details. |
